Patents by Inventor Christian Auclair

Christian Auclair has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11351146
    Abstract: The present invention relates to a composition comprising a combination of a (halogenoacetamido)benzoate, a flavonol and a terpene, and, as example, relates to a composition comprising the combination of ethyl 3-(2-chloroacetamido)benzoate, dihydroquercetin and bisabolol. Said composition is for use in the treatment of leishmaniasis, especially cutaneous or mucosal leishmaniasis, the composition being applied topically for concomitantly treating both parasitic infection and skin inflammation of the infected area induced by leishmaniasis.
    Type: Grant
    Filed: September 3, 2018
    Date of Patent: June 7, 2022
    Inventors: Christian Auclair, Esther Fellous, Patrice Le Pape, Jorge E. Kalil-Filho
  • Publication number: 20220142994
    Abstract: The invention provides a ?-carboline compound (an indole-containing compound) able to induce actin network remodeling in cancer cells into actin organized network and use thereof in non-cytotoxic cancer immunotherapy, for enhancing immune checkpoint inhibitor therapy, for activating cancer immune response, for treating or lessening the symptoms of, or preventing the human cancer, alone or in combination with one or more cancer immunotherapeutic agent for simultaneous, separate or sequential administration.
    Type: Application
    Filed: March 24, 2020
    Publication date: May 12, 2022
    Inventor: Christian AUCLAIR
  • Patent number: 11077087
    Abstract: Disclosed is the use of a composition including dihydroquercetin and optionally ?-tocopherol and/or bisabolol for treating herpes infection. Also disclosed is the use of such a composition for treating inflammation induced by herpes infection in mucosa, as well as a method for treating HSV infection and the associated inflammation.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: August 3, 2021
    Assignee: BIONOOX SUISSE SA
    Inventor: Christian Auclair
  • Publication number: 20210113523
    Abstract: The present invention relates to a composition combination for treating and/or preventing Photodynamic therapy side effects.
    Type: Application
    Filed: January 30, 2019
    Publication date: April 22, 2021
    Inventor: Christian AUCLAIR
  • Publication number: 20210113518
    Abstract: The invention provides the pharmaceutical composition and use thereof for treating or lessening the symptoms of, or preventing the symptoms of drug-induced phototoxicity or photosensitivity.
    Type: Application
    Filed: January 30, 2019
    Publication date: April 22, 2021
    Inventor: Christian AUCLAIR
  • Publication number: 20210059979
    Abstract: The present invention relates to a composition comprising a combination of a (halogenoacetamido)benzoate, a flavonol and a terpene, and, as example, relates to a composition comprising the combination of ethyl 3-(2-chloroacetamido)benzoate, dihydroquercetin and bisabolol. Said composition is for use in the treatment of leishmaniasis, especially cutaneous or mucosal leishmaniasis, the composition being applied topically for concomitantly treating both parasitic infection and skin inflammation of the infected area induced by leishmaniasis.
    Type: Application
    Filed: September 3, 2018
    Publication date: March 4, 2021
    Inventors: Christian Auclair, Esther Fellous, Patrice Le Pape, Jorge E. Kalil-Filho
  • Publication number: 20200261420
    Abstract: The use of a neoadjuvant prior to chemotherapy. A sphingosine-1-phosphate pathway activator for use in the treatment of cancer as a neoadjuvant prior to chemotherapy selected from sphingosine-1-phosphate lyase inhibitors. The sphingosine-1-phosphate pathway activator enhances the chemotherapy efficiency through the normalization of intratumoral vascular network, promoting the effects of the sequential administration of an anticancer agent or a sequential radiotherapy.
    Type: Application
    Filed: August 17, 2018
    Publication date: August 20, 2020
    Applicant: AC BIOSCIENCE
    Inventor: Christian AUCLAIR
  • Patent number: 10383955
    Abstract: The present invention relates to a human mast cell line corresponding to deposit number CNCM I-4551 and also to the lines derived therefrom, in particular the derived lines corresponding respectively to deposit numbers CNCM I-4552 and CNCM I-4553, and to the uses thereof, in particular for screening for compounds of therapeutic interest.
    Type: Grant
    Filed: November 2, 2012
    Date of Patent: August 20, 2019
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ECOLE NORMALE SUPERIEURE DE CACHAN, MEDIZINISCHE UNIVERSITAT WIEN
    Inventors: Michel Arock, Peter Valent, Rosine Saleh, Ghaith Wedeh, Christian Auclair
  • Patent number: 9956200
    Abstract: A method of using a composition including dihydroquercetin, as well as optionally ?-tocopherol and/or bisabolol, for treating the effects associated with skin inflammatory disorder, such as those associated with diseases characterized by inappropriate immune response, such as psoriasis, atopic dermatitis and/or urticaria. A process of manufacturing the composition is also described.
    Type: Grant
    Filed: February 18, 2015
    Date of Patent: May 1, 2018
    Assignee: BIONOOX SUISSE SA
    Inventor: Christian Auclair
  • Publication number: 20180055815
    Abstract: Disclosed is the use of a composition including dihydroquercetin and optionally ?-tocopherol and/or bisabolol for treating herpes infection. Also disclosed is the use of such a composition for treating inflammation induced by herpes infection in mucosa, as well as a method for treating HSV infection and the associated inflammation.
    Type: Application
    Filed: March 18, 2016
    Publication date: March 1, 2018
    Inventor: Christian AUCLAIR
  • Publication number: 20170246141
    Abstract: A method of using a composition including dihydroquercetin, as well as optionally ?-tocopherol and/or bisabolol, for treating the effects associated with skin inflammatory disorder, such as those associated with diseases characterized by inappropriate immune response, such as psoriasis, atopic dermatitis and/or urticaria. A process of manufacturing the composition is also described.
    Type: Application
    Filed: February 18, 2015
    Publication date: August 31, 2017
    Inventor: Christian AUCLAIR
  • Patent number: 9271956
    Abstract: A composition includes dihydroquercetin, ?-tocopherol and bisabolol. The use of the composition in a cosmetic method for limiting, alleviating and/or preventing cutaneous discomfort, especially cutaneous discomfort induced by a disease or induced by a therapy, a radiotherapy treatment and/or chemotherapy treatment, and the process of manufacturing the composition are also described.
    Type: Grant
    Filed: August 20, 2013
    Date of Patent: March 1, 2016
    Assignee: BIONOOX SUISSE SA
    Inventor: Christian Auclair
  • Publication number: 20150238459
    Abstract: A composition includes dihydroquercetin, ?-tocopherol and bisabolol. The use of the composition in a cosmetic method for limiting, alleviating and/or preventing cutaneous discomfort, especially cutaneous discomfort induced by a disease or induced by a therapy, a radiotherapy treatment and/or chemotherapy treatment, and the process of manufacturing the composition are also described.
    Type: Application
    Filed: August 20, 2013
    Publication date: August 27, 2015
    Inventor: Christian Auclair
  • Publication number: 20140298497
    Abstract: The present invention relates to a human mast cell line corresponding to deposit number CNCM I-4551 and also to the lines derived therefrom, in particular the derived lines corresponding respectively to deposit numbers CNCM I-4552 and CNCM I-4553, and to the uses thereof, in particular for screening for compounds of therapeutic interest.
    Type: Application
    Filed: November 2, 2012
    Publication date: October 2, 2014
    Inventors: Michel Arock, Peter Valent, Rosine Saleh, Ghaith Wedeh, Christian Auclair
  • Patent number: 8828718
    Abstract: The present invention relates to a gene transfer vector (GTV) and in particular to an integrating gene transfer vector (IGTV), which comprises at least one genetic insulator element (GIE), wherein the each comprises at least two copies of an element selected from the group consisting of: a CTF binding site; a first CTCF binding site and a second CTCF binding site, wherein the first and the second CTCF binding sites are derived from the regulatory sequences of different genes.
    Type: Grant
    Filed: April 2, 2010
    Date of Patent: September 9, 2014
    Assignee: Centre National de la Recherche Scientifique
    Inventors: Odile Cohen-Haguenauer, Christian Auclair
  • Patent number: 8227433
    Abstract: The present invention relates to a method for treating proliferative mastocytosis comprising administering a Bruton tyrosine kinase (BTK) inhibitor, a BTK antisense to a mammal in need of such treatment. The invention is more particularly suited for treating category II, III and IV mastocytosis.
    Type: Grant
    Filed: May 3, 2004
    Date of Patent: July 24, 2012
    Assignees: Centre National de la Recherche Scientifique (CNRS), Paris-Sud, Universite, Ecole Normale Superieure de Cachan
    Inventors: Christian Auclair, Frédéric Subra
  • Publication number: 20120115227
    Abstract: The present invention relates to a gene transfer vector (GTV) and in particular to an integrating gene transfer vector (IGTV), which comprises at least one genetic insulator element (GIE), wherein the each comprises at least two copies of an element selected from the group consisting of: a CTF binding site; a first CTCF binding site and a second CTCF binding site, wherein the first and the second CTCF binding sites are derived from the regulatory sequences of different genes.
    Type: Application
    Filed: April 2, 2010
    Publication date: May 10, 2012
    Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Odile Cohen-Haguenauer, Christian Auclair
  • Publication number: 20100216733
    Abstract: The present invention relates to a method for treating proliferative mastocytosis comprising administering a Bruton tyrosine kinase (BTK) inhibitor, a BTK antisense to a mammal in need of such treatment. The invention is more particularly suited for treating category II, III and IV mastocytosis.
    Type: Application
    Filed: May 3, 2004
    Publication date: August 26, 2010
    Inventors: Christian Auclair, Frédéric Subra
  • Publication number: 20090286720
    Abstract: A pharmaceutical composition for the treatment, prevention or diagnosis of a tumoral pathology comprising an active agent which stabilizes an actin network of a cellular cytoskeleton.
    Type: Application
    Filed: April 20, 2009
    Publication date: November 19, 2009
    Applicants: Bioalliance Pharma, Ecole Normale Superieure de Cachan, Institut Gustave Roussy - IGR, Centre National de la Recherche Scientifique - CNRS
    Inventors: Christian Auclair, Valerie Amsellem, Martial Hervy, Frederic Subra
  • Publication number: 20090197906
    Abstract: The invention relates to the use of 9-hydroxy ellipticine derivatives for the treatment of cancer. 9-hydroxy ellipticine derivatives may prove particularly useful for the treatment of metastatic cancers or cancers escaping conventional cytotoxic chemotherapies.
    Type: Application
    Filed: May 21, 2007
    Publication date: August 6, 2009
    Inventors: Christian Auclair, Valerie Polard, Andrei Maksimenko